

# Peter M Irving

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7647013/publications.pdf>

Version: 2024-02-01

217  
papers

11,363  
citations

26610

56  
h-index

33869

99  
g-index

229  
all docs

229  
docs citations

229  
times ranked

10322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Positioning intestinal ultrasound in a UK tertiary centre: significant estimated clinical role and cost savings. <i>Frontline Gastroenterology</i> , 2023, 14, 52-58.	0.9	3
2	Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1018-1035.	1.1	37
3	Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14241.	1.6	31
4	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	0.6	39
5	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	3.7	57
6	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	0
7	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	6.1	3
8	Depression, anxiety, and stress among inflammatory bowel disease patients during COVID-19: A UK cohort study. <i>JGH Open</i> , 2022, 6, 76-84.	0.7	7
9	Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 658-669.	1.9	7
10	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	3.7	100
11	Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. <i>Gastroenterology</i> , 2022, 162, 1512-1524.	0.6	44
12	Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn's Disease. <i>GastroHep</i> , 2022, 2022, 1-12.	0.3	0
13	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	5.8	48
14	Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 822-834.	0.6	3
15	Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1338-1347.	0.9	14
16	Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. <i>Frontline Gastroenterology</i> , 2022, 13, 517-523.	0.9	9
17	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet</i> , The, 2022, 399, 2200-2211.	6.3	94
18	A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 646-663.	1.9	14

#	ARTICLE	IF	CITATIONS
19	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 839-841.e2.	2.4	15
20	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	0.9	14
21	Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e32-e34.	0.9	10
22	COVID-19 and IBD drugs: should we change anything at the moment?. <i>Gut</i> , 2021, 70, 632-634.	6.1	11
23	Striking the balance with intravenous iron: too much or never enough?. <i>Frontline Gastroenterology</i> , 2021, 12, 361-362.	0.9	0
24	Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. <i>Clinical Nutrition</i> , 2021, 40, 1861-1870.	2.3	44
25	Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol. <i>Evidence-Based Mental Health</i> , 2021, 24, 82-87.	2.2	3
26	Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2021, 70, 1044-1052.	6.1	13
27	Vedolizumab Dose Escalation: In for a Penny, in for a Pound?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1772-1774.	1.1	1
28	P334...Measuring oesophageal transit with multichannel intraluminal impedance; an alternative to barium swallow. , 2021, , .		0
29	P339...Novel approach to assess retention in dysphagia patients with post anti-reflux surgery. , 2021, , .		0
30	P338...Assessing oesophageal clearance in post peroral endoscopic myotomy: introducing a novel technique. , 2021, , .		0
31	P340...Oesophageal transit during fasting and non-fasting period in patients with dysphagia. , 2021, , .		0
32	P333...Baseline mucosal impedance predicting the outcome of bravo pH study. , 2021, , .		0
33	P337...Evaluating modern reflux monitoring methods with respect to medical therapy. , 2021, , .		0
34	Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. <i>BioDrugs</i> , 2021, 35, 187-199.	2.2	3
35	Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000573.	1.1	42
36	Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study. <i>Evidence-Based Mental Health</i> , 2021, 24, 102-109.	2.2	26

#	ARTICLE	IF	CITATIONS
37	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	6.1	153
38	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	6.1	233
39	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	3.7	23
40	A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2054-2065.	0.6	5
41	An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 678-688.	1.9	7
42	Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 341-342.	1.9	2
43	Nutrient, Fibre, and FODMAP Intakes and Food-related Quality of Life in Patients with Inflammatory Bowel Disease, and Their Relationship with Gastrointestinal Symptoms of Differing Aetiologies. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2041-2053.	0.6	23
44	P336...Multichannel intraluminal impedance transit in patients with obstructive disorders. , 2021, , .		0
45	P335...Multichannel intraluminal impedance transit testing in patients with functional dysphagia. , 2021, , .		0
46	S770...Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: IBDQ in the SEAVUE Study. <i>American Journal of Gastroenterology</i> , 2021, 116, S355-S357.	0.2	1
47	Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. <i>Circulation: Heart Failure</i> , 2021, 14, .	1.6	7
48	Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 535-547.	0.4	73
49	Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. <i>Gastroenterology</i> , 2020, 158, 176-188.e7.	0.6	209
50	Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 908-916.e13.	2.4	18
51	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	0.6	249
52	The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. <i>GastroHep</i> , 2020, 2, 318-326.	0.3	14
53	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	0.9	37
54	Authors' Reply to: Type C Mucosa in Pouch Surveillance: Make-do and Mend Rather Than Start From Scratch?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1181-1181.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. <i>Frontline Gastroenterology</i> , 2020, 11, 188-193.	0.9	14
56	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
57	Tofacitinib in Acute Severe Ulcerative Colitis—A Real-World Tertiary Center Experience. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e147-e149.	0.9	28
58	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1653-1661.	0.6	9
59	Î²-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. <i>American Journal of Gastroenterology</i> , 2020, 115, 906-915.	0.2	50
60	Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 292-302.	1.9	17
61	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	6.1	28
62	Regulatory T-cell therapy in Crohn's disease: challenges and advances. <i>Gut</i> , 2020, 69, 942-952.	6.1	99
63	Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e125-e126.	0.9	10
64	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1769-1776.	0.6	13
65	New role for azathioprine in case of switching anti-TNFs in IBD. <i>Gut</i> , 2020, 69, 1165-1167.	6.1	6
66	Editorial: establishing a joint approach to a common problem for gastroenterologists. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 306-307.	1.9	2
67	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
68	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1385-1393.	0.6	74
69	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	6.1	232
70	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. <i>RMD Open</i> , 2020, 6, e001392.	1.8	26
71	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020, 33, 170-177.	0.4	13
72	Letter: immune checkpoint inhibitor-induced colitis—shouldn't we be checking more often?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 472-473.	1.9	1

#	ARTICLE	IF	CITATIONS
73	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e143-e145.	0.9	13
74	Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients. <i>Scientific Reports</i> , 2019, 9, 14042.	1.6	24
75	Recent advances in monoclonal antibody therapy in IBD: practical issues. <i>Frontline Gastroenterology</i> , 2019, 10, 409-416.	0.9	27
76	De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. <i>GastroHep</i> , 2019, 1, 108-117.	0.3	3
77	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1655-1668.e3.	2.4	214
78	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	3.7	431
79	Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor- $\alpha$ . <i>Gastroenterology</i> , 2019, 156, 1775-1787.	0.6	40
80	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
81	Golimumab in the treatment of ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882126.	1.4	13
82	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. <i>Medicine (United States)</i> , 2019, 98, e14681.	0.4	5
83	Positioning biologics and new therapies in the management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 296-301.	1.0	5
84	Faecal microbiota transplantation for refractory <i>Clostridium difficile</i> infection. <i>BMJ Case Reports</i> , 2019, 12, e231027.	0.2	2
85	Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?. <i>Frontiers in Medicine</i> , 2019, 6, 279.	1.2	15
86	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 735-743.	0.6	24
87	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 937-944.	0.9	29
88	Biologic therapies for Crohn's disease: optimising the old and maximising the new. <i>F1000Research</i> , 2019, 8, 1210.	0.8	25
89	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
90	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1829-1831.	2.4	4

#	ARTICLE	IF	CITATIONS
91	Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent <i>Clostridium difficile</i> Infection in Two English Hospitals: A Review. <i>Infectious Diseases and Therapy</i> , 2018, 7, 71-86.	1.8	45
92	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 714-724.	0.9	102
93	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
94	A practical guide to thiopurine prescribing and monitoring in IBD. <i>Frontline Gastroenterology</i> , 2018, 9, 10-15.	0.9	53
95	Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13154.	1.6	132
96	Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 385-391.e1.	2.4	90
97	Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2018, 9, 221-231.	0.9	12
98	The ÎTTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. <i>Nature Immunology</i> , 2018, 19, 1352-1365.	7.0	163
99	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1051-1058.	0.6	12
100	Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1271-1279.	1.4	15
101	Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in) <a href="#">Tj ETQq1 1 0.784314 rg84 / Over</a>	0.7	84
102	Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. <i>Digestive Diseases</i> , 2018, 36, 33-39.	0.8	6
103	IBD2020 global forum: results of an international patient survey on quality of care. <i>Intestinal Research</i> , 2018, 16, 537-545.	1.0	20
104	Successful faecal microbiota transplant for recurrent <i>Clostridium difficile</i> infection delivered by colonoscopy through a diverted ileostomy in a patient with severe perianal Crohn's disease. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222958.	0.2	2
105	The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study. <i>JMIR Research Protocols</i> , 2018, 7, e11218.	0.5	3
106	Utilisation of anti-TNF levels in a UK tertiary IBD centre. <i>Frontline Gastroenterology</i> , 2017, 8, 189-195.	0.9	2
107	Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2017, 8, 196-202.	0.9	41
108	Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. <i>United European Gastroenterology Journal</i> , 2017, 5, 563-570.	1.6	30

#	ARTICLE	IF	CITATIONS
109	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 150-161.	1.9	53
110	A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2017, 153, 936-947.	0.6	315
111	The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 203-212.	0.4	83
112	Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1420-1429.	0.6	100
113	Biologic Therapy of Ulcerative Colitis: Golimumab. , 2017, , 441-448.		0
114	The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 628-628.	0.4	14
115	Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 465-465.	1.9	0
116	Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1555-1565.	0.9	21
117	Optimising use of thiopurines in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 877-888.	1.3	17
118	ECCO IBD Curriculum. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1039-1043.	0.6	5
119	Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 57-66.	1.0	8
120	Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1418-1424.	0.9	21
121	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1302-1309.	2.4	36
122	1133 The Low FODMAP Diet Reduces Symptoms in Irritable Bowel Syndrome Compared With Placebo Diet and the Microbiota Alterations May Be Prevented by Probiotic Co-Administration: A 2x2 Factorial Randomized Controlled Trial. <i>Gastroenterology</i> , 2016, 150, S230.	0.6	8
123	Characterisation of the lymphoid stress surveillance response in human intestine. <i>Lancet</i> , The, 2016, 387, S33.	6.3	0
124	Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific T Cell Compartments. <i>Cell</i> , 2016, 167, 203-218.e17.	18.5	273
125	Patient optimization for surgery relating to Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 707-719.	8.2	92
126	Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw189.	0.6	43

#	ARTICLE	IF	CITATIONS
127	Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, E39-E40.	0.9	22
128	The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 975-977.	1.4	3
129	Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. <i>Frontline Gastroenterology</i> , 2016, 7, 122-128.	0.9	36
130	Developing in vitro expanded CD45RA <sup>+</sup> regulatory T cells as an adoptive cell therapy for Crohn's disease. <i>Gut</i> , 2016, 65, 584-594.	6.1	163
131	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	0.6	85
132	Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1129-1136.	0.9	137
133	Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 910-923.	1.9	87
134	Association Between Response to Etrolizumab and Expression of Integrin $\beta$ 4 and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133
135	Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 687-696.	1.3	73
136	Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2839-2847.	0.9	42
137	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2015, 21, 11331.	1.4	3
138	Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. <i>Gastroenterology</i> , 2015, 149, 456-467.e15.	0.6	71
139	Toxicity and response to thiopurines in patients with inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 891-900.	1.4	37
140	Biosimilars: what's around the corner?. <i>Frontline Gastroenterology</i> , 2015, 6, 262-263.	0.9	1
141	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2233-2240.e2.	2.4	109
142	Distinct management issues with Crohn's disease of the small intestine. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 92-97.	1.0	4
143	Are We Using and Monitoring Thiopurines and Biologics Optimally?. <i>Digestive Diseases</i> , 2014, 32, 410-418.	0.8	4
144	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1313-1323.	1.9	55

#	ARTICLE	IF	CITATIONS
145	Hidradenitis Suppurativa. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 762-771.	0.7	35
146	Can we get more from our current treatments?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 451-463.	1.0	3
147	Mechanisms and efficacy of dietary FODMAP restriction in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 256-266.	8.2	198
148	Oesophageal Crohn's disease: A novel approach to managing iatrogenic perforation of an oesophageal Crohn's stricture. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 332-333.	0.6	0
149	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
150	Use of azathioprine in IBD: modern aspects of an old drug. <i>Gut</i> , 2014, 63, 1695-1699.	6.1	32
151	Improving quality of care in inflammatory bowel disease: What changes can be made today?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 919-926.	0.6	65
152	343 Azathioprine Decreases the Risk of Adalimumab Primary Non-Response and Secondary Loss of Response but Only if Adequately Dosed. <i>Gastroenterology</i> , 2014, 146, S-79.	0.6	3
153	Current management options and recent advances in IBD. <i>The Prescriber</i> , 2014, 25, 18-22.	0.1	0
154	Inflammatory bowel disease in pregnancy: management strategy based on best evidence and European guidelines. <i>British Journal of General Practice</i> , 2014, 64, 593-594.	0.7	5
155	979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data. <i>Gastroenterology</i> , 2013, 144, S-179.	0.6	12
156	Alopecia areata: A possible extraintestinal manifestation of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e503.	0.6	4
157	The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. <i>International Journal of Clinical Practice</i> , 2013, 67, 161-169.	0.8	52
158	Mechanism of allopurinol induced TPMT inhibition. <i>Biochemical Pharmacology</i> , 2013, 86, 539-547.	2.0	96
159	Semiquantitative assessment of breath hydrogen testing. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1450-1456.	1.4	4
160	Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1097-1108.	1.9	65
161	Hair Loss in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1753-1763.	0.9	18
162	Steroids in villous atrophy: opening a can of worms?. <i>Frontline Gastroenterology</i> , 2012, 3, 199-200.	0.9	0

#	ARTICLE	IF	CITATIONS
163	The future developments in inflammatory bowel disease care: Table 1. <i>Frontline Gastroenterology</i> , 2012, 3, i42-i46.	0.9	2
164	Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. <i>Journal of Nutrition</i> , 2012, 142, 1510-1518.	1.3	430
165	Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 685-689.	0.9	21
166	Anti-infliximab antibodies in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1078-1085.	0.8	59
167	What changes in inflammatory bowel disease management can be implemented today?. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S260-S267.	0.6	5
168	Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 905-912.	0.6	92
169	Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2294-2300.	0.9	10
170	Small bowel MR enterography: problem solving in Crohn's disease. <i>Insights Into Imaging</i> , 2012, 3, 251-263.	1.6	75
171	Fructan content of commonly consumed wheat, rye and gluten-free breads. <i>International Journal of Food Sciences and Nutrition</i> , 2011, 62, 498-503.	1.3	67
172	Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 508-514.	0.2	606
173	Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 487-495.	1.3	350
174	Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1301-1307.	0.9	91
175	Cutting Edge: Regulator of G Protein Signaling-1 Selectively Regulates Gut T Cell Trafficking and Colitic Potential. <i>Journal of Immunology</i> , 2011, 187, 2067-2071.	0.4	78
176	Poster presentations at medical conferences: an effective way of disseminating research?. <i>Clinical Medicine</i> , 2011, 11, 138-141.	0.8	36
177	Optimization of conventional therapy in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 646-656.	8.2	66
178	Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorption. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 318-326.	0.8	58
179	The Glasgow Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage. <i>International Journal of Clinical Practice</i> , 2010, 64, 868-874.	0.8	47
180	Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 874-882.	1.9	295

#	ARTICLE	IF	CITATIONS
181	Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 119-130.	1.9	88
182	Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1366-1373.	1.4	476
183	The Appropriateness of Concomitant Immunomodulators With Anti-Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 655-659.	2.4	46
184	Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. <i>Pharmacogenomics</i> , 2009, 10, 1091-1099.	0.6	9
185	Recent advances in the management of inflammatory bowel disease. <i>Clinical Medicine</i> , 2009, 9, 605-608.	0.8	1
186	Optimizing conventional therapies for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2009, 11, 496-503.	1.1	11
187	Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 165-174.	1.9	131
188	Biologics for inflammatory bowel diseases in the Asia-Pacific: Can we afford to use them, can we afford not to?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1160-1162.	1.4	6
189	Quality, clinical influence and tolerance of computed tomography enteroclysis in patients with suspected small bowel disease. <i>Internal Medicine Journal</i> , 2009, 39, 733-743.	0.5	6
190	Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 8-14.	0.6	256
191	Management of distal ulcerative colitis: frequently asked questions analysis. <i>Internal Medicine Journal</i> , 2008, 38, 114-119.	0.5	13
192	Infections and IBD. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2008, 5, 18-27.	1.7	86
193	Drug Interactions in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 207-219.	0.2	19
194	Platelet-leucocyte aggregates form in the mesenteric vasculature in patients with ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 283-289.	0.8	33
195	Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2008, 14, 5020.	1.4	63
196	Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGE Group. <i>Gastroenterology and Hepatology</i> , 2008, 4, 713-20.	0.2	0
197	Platelet-leucocyte aggregation in IBD. <i>American Journal of Hematology</i> , 2007, 82, 686-686.	2.0	2
198	Infliximab: Getting the most for your money. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1559-1561.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Gastrointestinal: Rapunzel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 2361-2361.	1.4	17
200	Review article: appropriate use of corticosteroids in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 313-329.	1.9	77
201	Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. European Journal of Gastroenterology and Hepatology, 2006, 18, 249-253.	0.8	70
202	Diversion Colitis Caused by Clostridium difficile Infection: Report of a Case. Diseases of the Colon and Rectum, 2006, 49, 1074-1077.	0.7	21
203	Leukocytapheresis in Ulcerative Colitis. American Journal of Gastroenterology, 2006, 101, 203-204.	0.2	0
204	Acute mesenteric infarction: an important cause of abdominal pain in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2005, 17, 1429-1432.	0.8	14
205	Thrombosis and Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2005, 3, 617-628.	2.4	134
206	Formation of Platelet-leukocyte Aggregates in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 361-372.	0.9	92
207	Leucocytapheresis for ulcerative colitis. Digestive and Liver Disease, 2004, 36, 799-802.	0.4	7
208	Diverticular disease of the colon. Lancet, The, 2004, 363, 1397.	6.3	2
209	Percutaneous endoscopic gastrostomy with a jejunal port for severe hyperemesis gravidarum. European Journal of Gastroenterology and Hepatology, 2004, 16, 937-939.	0.8	23
210	Colonoscopy completion rates: Technologies have evolved. BMJ: British Medical Journal, 2004, 329, 1287.3.	2.4	0
211	An audit of admissions of patients with epilepsy to a district general hospital. Seizure: the Journal of the British Epilepsy Association, 1999, 8, 166-169.	0.9	15
212	Pulmonary Manifestations: Rare But Real. , 0, , 213-216.		0
213	Intestinal Infections: Mimics and Precipitants of Relapse. , 0, , 217-221.		1
214	Leukocytapheresis: Filtering Out the Facts. , 0, , 105-107.		0
215	CMV co-Infection" Does it Matter?. , 0, , 159-163.		2
216	Thromboembolic Disease: An Under-Recognized Complication?. , 0, , 209-212.		0

#	ARTICLE	IF	CITATIONS
217	Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel. <i>Journal of Crohn's and Colitis</i> , 0, , .	0.6	3